BTK Inhibitor Crystal Polymorphs for Reproducible Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel crystalline forms of the BTK inhibitor Compound (I) with desirable physical and pharmaceutical properties for large-scale manufacturing and pharmaceutical formulation, as well as reproducible methods for producing these forms, due to the unpredictability of solid forms and their properties in existing technologies.
Innovation Solution
Development of novel crystalline forms of Compound (I), specifically Crystalline Forms A, B, and C, characterized by unique X-ray powder diffraction patterns, differential scanning calorimetry thermograms, and thermogravimetric analysis, along with scalable preparation methods such as solvent-based crystallization processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional solid form prediction methods are used, then the development process is unpredictable, but this leads to difficulties in achieving reproducible manufacturing and formulation
Solution Approach 1:
The patent applies preliminary action by conducting exhaustive solid form screening and characterization before pharmaceutical development. Multiple crystalline forms (Forms I, II, III, IV) are identified and characterized in advance using XRPD, DSC, and solubility studies, allowing the most suitable form to be selected for development before manufacturing and formulation processes begin, thereby ensuring predictability and reproducibility throughout the product lifecycle
2Adaptability or versatility
If multiple crystalline forms are developed, then pharmaceutical properties can be optimized, but the complexity of characterizing and selecting the optimal form increases
Solution Approach 1:
The patent applies parameter changes by systematically varying crystallization conditions (solvent type, temperature, pH, concentration) to generate different crystalline forms with distinct pharmaceutical properties. Each form is characterized by specific XRPD patterns and DSC profiles, allowing systematic comparison and selection based on desired properties such as solubility, stability, and bioavailability, thereby optimizing pharmaceutical performance while managing characterization complexity through standardized methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel crystalline forms exhibit improved stability, solubility, and ease of formulation, enabling effective BTK inhibition for treating immune-mediated diseases, with enhanced pharmaceutical properties suitable for large-scale manufacturing and storage.
Implementation Method 1
characterized by unique X-ray powder diffraction patterns
Implementation Method 2
characterized by unique X-ray powder diffraction patterns
Implementation Method 3
differential scanning calorimetry thermograms
Implementation Method 4
thermogravimetric analysis
Data Source
AI summary
Crystalline forms of Compound (I):are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.